Abstract 133P
Background
The use of CAR-T therapy for treating solid tumors has encountered challenges due to the structure and immunological properties of the tumors. However, microvesicles, which represent cell-free biosimilar drugs, offer a promising solution to overcome these obstacles. One of the main issues faced in this approach is the small yield of microvesicles from the cell sources. This challenge can be addressed by incorporating various induction methods such as ultrasonication.
Methods
T lymphocytes and anti-CD19 CAR-T cells were activated by CD3/CD28 abs for 24 h, then ultrasonication was used to obtain artificial vesicles (AVs) – T-AVs and CAR-T-AVs, respectively. AVs were isolated by differential centrifugation and analyzed with scanning electron microscopy (SEM) using Merlin (Carl Zeiss). Then the cytotoxic efficacy of AVs against PC3M and PC3M(CD19+) tumor cells was tested using xCelligence real-time cell analysis (RTCA) system.
Results
SEM data: CAR-T-AVs (n=263) were predominantly smaller in size than T-AVs (n=376). The major population was represented by 51-75 nm particles with a narrow monodisperse peak. Whereas for T-AVs, most particles the size distribution was much wider, in the range of 75-200 nm. RTCA data: for PC3M control, neither added T/CAR-T cells nor their respective AVs had any significant effect on tumor cell proliferation. Opposite to that, for the PC3M(CD19+) tumor line, the cell index began to decrease 30 hrs after CAR-T-AVs addition – interestingly, with more pronounced effect in the wells with a lower concentration of vesicles (10 μg/ml). Both T-AVs and CAR-T-AVs showed a less pronounced cytotoxic effect at higher concentration (35 μg/ml), potentially due to nonspecific toxicity.
Conclusions
Ranging particles size distribution may indicate diverse dynamics in the cell membrane and intracellular content in response to activation of T/CAR-T cells and treatment with ultrasonic. Doze-dependence of CAR-T-AVs cytotoxicity and their detailed mechanism of action shall be addressed in the future studies. The work was funded by the Russian Science Foundation grant 23-24-00224 and performed in accordance with the Strategic Academic Leadership Program of the Kazan (Volga Region) Federal University (PRIORITET-2030).
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The work was funded by the Russian Science Foundation grant 23-24-00224 and performed in accordance with the Strategic Academic Leadership Program of the Kazan (Volga Region) Federal University (PRIORITET-2030).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract